Graft rejection following bone marrow transplantation is more common in patients who receive their grafts from alternative donors and whose marrow is T cell depleted. Rejection in these patients is mediated by persistent host cells that interfere with successful establishment of donor-derived hematopoietic recovery. We describe a patient with chronic myelogenous leukemia in accelerated phase who rejected a T cell-depleted bone marrow graft, 2 months following partially mismatched related donor bone marrow transplant. Unmanipulated peripheral blood donor leukocyte infusion, without additional chemotherapy or immunosuppressive therapy resulted in complete hematopoietic recovery. Cytogenetics and RFLP demonstrated hematopoietic donor chimerism. The patient did not develop graft-versushost disease. Keywords: bone marrow transplantation; graft rejection; donor leukocyte infusion; partially mismatched related donor; CML Graft rejection following BMT remains a significant problem associated with the use of an alternative donor 1 T cell depletion 2 and the diagnosis of CML. 3 Patients who experience immune-mediated graft rejection have evidence of persistent host cells 4 that interfere with engraftment of the HLA disparate hematopoietic graft. Engraftment of additional donor cells requires ablation of allosensitized host cells. However, treatment to eradicate host cells predisposes the patient to life-threatening infection and additional organ dysfunction. To avoid these complications, we treated graft rejection with donor leukocyte infusion (DLI) alone, and in this report we demonstrate that longterm hematopoietic recovery was established.
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Case report
A 30-year-old Jamaican male was diagnosed with Ph + chronic myelogenous leukemia in September 1993. Initial treatment included hydroxyurea and interferon but due to progression of disease, nitrogen mustard and high-dose cytosine arabinoside were given in May 1994. Lacking an HLA-matched sibling, the patient was referred for a partially mismatched related donor (PMRD) allogeneic transplant. The best available donor was his son who was bidirectional (rejection and GVHD directions) 2 antigen mismatched (Table 1) . Conditioning therapy included total body irradiation and chemotherapy as previously described. 5 GVHD prophylaxis included T cell depletion of the graft with OKT3 antibody, and post-transplant immunosuppression. 5 The marrow graft contained 5.18 × 10 7 nucleated cells and 6.67 × 10 5 mature T cells per kg recipient weight. To enhance engraftment, G-CSF at 480 g/day was given daily. His immediate post-transplant course was complicated by mucositis, Pseudomonas urinary tract infection and hemolytic uremic syndrome all resolved. On day +14, the patient's WBC count was at 0.6 K/l and bone marrow aspiration showed 10% cellularity, with histologic evidence of trilineage engraftment and no evidence of recurrent leukemia (Table 1) . During the next 2 weeks his counts continued to recover, confirmed by bone marrow aspiration and biopsy on day +28, however, flow cytometric evaluation of the peripheral blood revealed an increased proportion of CD3 +
CD8
+ HLA-DR + T lymphocytes with a parallel decline in CD56 + NK population. The appearance of this population early following PMRD-BMT had previously been associated with impending graft rejection. 2, 6 Of interest, due to complaints of abdominal pain, a colon biopsy was obtained, and its findings were suggestive of mild acute GVHD. By day 32 post-transplant, he developed low-grade fever and continued to complain of abdominal pains. An upper gastrointestinal endoscopy and duodenal biopsy revealed inflammation without signs of GVHD. Pan surveillance cultures and CT scan of the abdomen were unrevealing. By day 48 post transplant, his WBC had gradually fallen to 0.6 K/l and bone marrow examination revealed hypocellular marrow with evidence of hemophagocytosis. Evaluation of hematopoietic chimerism using . TLE = trilineage engraftment; NEL = no evidence of leukemia; HPC = hemophagocytosis; EOS = eosinophilia; D = donor; H = host; E = equivocal; TE/BM = total engraftment (bone marrow sample); TE/BL = total engraftment (blood sample); QNS = quantity not sufficient.
HLA typing and flow cytometric analysis was suggestive of mixed chimera, as serologic testing showed donor-specific A23, and the emerging CD3
+ cells co-expressed HLA-DR11 (1 Lambda, Canoga Park, CA, USA) positivity, indicating host origin. TCR-V␤ analysis of sorted CD3 + CD8 + /HLA-DR + T cells, revealed expression of V␤11 and V␤16. The patient was given G-CSF at increasing doses of 300 to 960 g and then changed to GM-CSF at 1000 g daily with minimal response. Other possible causes of pancytopenia were sought; marrow cells were analyzed by PCR analysis for CMV, EBV, Herpes I, II and VI and were all negative. Drug-induced neutropenia was considered and ganciclovir prophylaxis was discontinued with no improvement. Subsequently, cyclosporine was discontinued and donor leukocyte infusion (DLI) at 9.9 × 10 6 nucleated cells/kg containing 5.3 × 10 6 CD3 + cells/kg was infused. Over the following days, his WBC began to recover and RFLP analysis showed total donor engraftment, also confirmed by cytogenetic analysis. FACS analysis showed predominance of CD3 + cells with TCR-V␤ change in expression to V␤4, 5.1, 7, 10, 14, 17, 19, 20 and 22. Further examination of the TCR-V␤ repertoire at 100 and 180 days post BMT revealed increased V␤ diversity but no other shift of expression. The patient did not develop any additional signs of GVHD. He is currently well 2 years following DLI with no evidence of chronic GVHD.
Discussion
The patient's clinical course and the laboratory data were consistent with impending graft rejection. Kernan and others who studied graft failure in HLA-nonidentical T celldepleted transplants, characterized rejection by the detection of host CD3
+ CD8 + T cell subsets, while patients develop abrupt neutropenia. 2, 6 Detection of these specific host T cell subsets in our patient in the context of falling counts, was highly suggestive of impending graft failure. Recognition of the role that T cells play in promoting engraftment 7 led us to use donor peripheral blood in these circumstances. The use of DLI has been reported initially as adoptive immunotherapy in relapsed leukemia, 8, 9 and later as treatment for EBV lymphoproliferative disorders. 10 More recently, peripheral blood stem cells have been used to successfully establish hematopoietic engraftment. 11 We and others [12] [13] [14] have previously described the use of DLI from a haploidentical donor to treat patients who relapsed post BMT or those with graft failure. Unlike this report, when peripheral blood stem cells have been given for graft failure or rejection, their collection was preceded by growth factor administration, to enrich for early hematopoietic progenitors.
14-15 Our patient received unmobilized DLI containing a small number of progenitor cells; therefore, his recovery was thought to imply immunological ablation of 'rejection host cells' rather than a result of rapid expansion from a 'boost' of primitive stem cells.
The analysis of peripheral blood cells when the WBC count dropped showed a predominance of CD8 positivity, displaying a limited TCR repertoire which appeared to represent emerging host lymphocytes as identified by concomitant HLA analysis ( Table 1) . As the peripheral WBC count recovered following DLI, TCR oligoclonality was replaced by a variable donor repertoire of T cells, confirmed by RFLP analysis. This is the first report of DLI from PMRD given to treat graft rejection, without pretreatment with immunosuppressants or chemotherapy. Administration of haploidentical DLI had been associated with the development of GVHD. 12, 13 Our patient did not develop any evidence of GVHD despite the withdrawal of cyclosporine, perhaps due to the low T cell dose given. Infused nucleated cell dose appears to be a factor in the development of GvHD as suggested by Pati et al, 16 who studied patients given preemptive DLI early post PMRD-BMT. This report implied that patients who received Ͼ10 7 mononuclear cells/kg had an increased incidence and severity of acute GVHD. In two other patients reported to receive PMRD-DLI, the number of mononuclear cells was 0.8-3 × 10 8 cells/kg and both patients developed GVHD. 12, 14 When T cell number was evaluated, there appeared to be a very wide range of cell dose infused (between 0.34 × 10 6 and 2.4 × 10 8 CD3 + cells/kg) which could not be directly correlated with the high incidence of severe GVHD seen. Although within this range, our patient who received 5.3 × 10 6 CD3 + cells/kg, did not develop any evidence of GVHD.
Taken together, it appears that the number of cells infused is not the only risk factor for the developing of acute GVHD, but other determinants related to the donor and recipient appear to play a role. Factors may include specific major and minor HLA differences, gender or age disparity, time post transplant, and co-existing infections. Infused donor leukocytes have a potent immunomodulatory effect that can be used to reverse graft rejection, but may also cause severe GVHD. The extraordinarily high mortality associated with allogeneic graft rejection warrants the use of DLI with prompt treatment for early signs of acute GVHD.
